批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2021/11/04 |
SUPPL-46(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/10/25 |
SUPPL-45(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2019/04/25 |
SUPPL-44(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2017/06/09 |
SUPPL-43(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2015/09/14 |
SUPPL-42(补充) |
Approval |
Efficacy |
PRIORITY
;Orphan
|
|
|
2015/08/20 |
SUPPL-41(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/10/08 |
SUPPL-40(补充) |
Approval |
Efficacy |
PRIORITY
;Orphan
|
|
|
2014/09/08 |
SUPPL-39(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/08/08 |
SUPPL-38(补充) |
Approval |
Efficacy |
STANDARD
;Orphan
|
|
|
2014/03/13 |
SUPPL-37(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/08/05 |
SUPPL-36(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/08/02 |
SUPPL-35(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/04/01 |
SUPPL-33(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2012/10/26 |
SUPPL-32(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/10/26 |
SUPPL-31(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/01/23 |
SUPPL-27(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2011/11/01 |
SUPPL-30(补充) |
Approval |
Efficacy |
STANDARD
;Orphan
|
|
|
2011/11/01 |
SUPPL-29(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/04/07 |
SUPPL-28(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/12/03 |
SUPPL-23(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2009/12/30 |
SUPPL-20(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2009/12/30 |
SUPPL-19(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2009/04/24 |
SUPPL-18(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2008/06/20 |
SUPPL-15(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2007/10/10 |
SUPPL-13(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2006/12/08 |
SUPPL-10(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2006/05/31 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/12/08 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/03/25 |
SUPPL-6(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2004/05/25 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/05/13 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:BORTEZOMIB 剂型/给药途径:INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 规格:3.5MG/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021602 |
001 |
NDA |
VELCADE |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
Yes |
Yes |
AP |
2003/05/13
|
TAKEDA PHARMS USA |
205533 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
APOTEX |
205857 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Discontinued |
No |
No |
AP |
2022/05/02
|
TEVA PHARMS USA |
208392 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
PHARMASCIENCE INC |
209659 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
FRESENIUS KABI USA |
210204 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
ZYDUS PHARMS |
210824 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
QILU PHARM HAINAN |
212825 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
EUGIA PHARMA |
213823 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/05/02
|
BAXTER HLTHCARE CORP |
215011 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
JIANGSU HANSOH PHARM |
212958 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
MEITHEAL |
208460 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
HOSPIRA |
209622 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
MSN |
202963 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
DR REDDYS |
203654 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/07/26
|
SANDOZ |
204405 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Discontinued |
No |
No |
AP |
2022/07/26
|
ACCORD HLTHCARE |
211898 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2022/10/11
|
RELIANCE LIFE SCI |
205160 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Discontinued |
No |
No |
AP |
2022/10/31
|
NORVIUM BIOSCIENCE |
216912 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Discontinued |
No |
No |
AP |
2023/09/26
|
SCINOPHARM TAIWAN |
212204 |
001 |
ANDA |
BORTEZOMIB |
BORTEZOMIB |
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS |
3.5MG/VIAL |
Prescription |
No |
No |
AP |
2024/05/03
|
HETERO LABS LTD VI |